HIGHLIGHTS
- who: GMJ and colleagues from the University of Medical Sciences, Tabriz, Iran have published the Article: Drug Resistance and Cardiovascular Safety of Second-Generation Anti-Androgens in Patients with Advanced Prostate Cancer, in the Journal: (JOURNAL)
- what: The reviewed studies revealed that mutation and other genetic anomalies resulted in prostate cancer cells` resistance to two firstly approved members of next-generation antiandrogens, including abiraterone acetate and enzalutamide.
SUMMARY
A variety of genetic and epigenetic alterations, such as androgen receptor hyperactivation by amplification and/or mutation, amplification of the MYC oncogene, PD . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.